Synjardy is a tablet containing empagliflozin (an SGLT2 inhibitor) and metformin (a biguanide). It helps lower blood sugar in people with Type 2 diabetes when used with a balanced diet and regular exercise. Synjardy can also help lower the risk of serious problems in adults with Type 2 diabetes who have heart disease, heart failure, or chronic kidney disease (CKD). Immediate-release tablets (IR) are for people 10 years and older and are taken twice a day. The extended-release tablets (XR) are only for adults and are taken once a day. Side effects include urinary tract infections and genital yeast infections.
Indications of Jardiance vs. Synjardy
Indications for
•Type 2 diabetes (in addition to diet and exercise) in people age 10 years and older
•Lowering the risk of death due to heart problems in adults with Type 2 diabetes and heart disease
•Lowering the risk of hospitalization and death due to heart problems in adults with heart failure
•Lowering the risk of worsening kidney problems, hospitalization, and death due to heart problems in adults with chronic kidney disease (CKD)
•Lowering the risk of death due to heart problems in adults with Type 2 diabetes and heart disease
•Lowering the risk of hospitalization and death due to heart problems in adults with Type 2 diabetes and heart failure
•Lowering the risk of worsening kidney problems, hospitalization, and death due to heart problems in adults with Type 2 diabetes and chronic kidney disease (CKD)